3716.TW Cenra Inc.
- Market cap
- TWD 4.83B
- P/E
- 8.1x
- P/B
- 0.63x
- ROE
- 9.8%
- Dividend yield
- 3.08%
- Fundamental score
- -
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 3716.TW undervalued?
Graham number3716.TW trades 52.5% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Cenra Inc. fundamental analysis
No fundamental analysis for Cenra Inc. yet.
Cenra Inc. stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Cenra Inc.
Cenra Inc. engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals. It provides CDMO services for internal and external partners; oral solids, injectables, specialty formulations, and APIs, supported by process development, scale-up, and regulatory support; oral solids, injectables, specialty formulations, and high-purity active pharmaceutical ingredients (APIs), supported by process development,…
Full company profileCenra Inc. financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
Cenra Inc. annual financial statements (TWD; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 7.95B | 8.46B | 8.57B | 8.92B | 8.57B | 8.46B |
| Gross Profit | 2.86B | 3.09B | 3.14B | 3.41B | 3.32B | 3.38B |
| Operating Income | 411M | 369M | 239M | 299M | 428M | 589M |
| EBITDA | - | 922M | 765M | 805M | 828M | 1.33B |
| Net Income | 518M | 478M | 322M | 317M | 300M | 751M |
| EPS | 3.47 | 3.20 | 2.16 | 2.13 | 2.05 | 5.16 |
| Balance Sheet | ||||||
| Total Assets | 12.8B | 12.8B | 12.9B | 12.8B | 12.4B | 12.3B |
| Total Liabilities | 5.00B | 5.39B | 5.39B | 5.22B | 4.84B | 4.65B |
| Shareholders' Equity | 7.75B | 7.39B | 7.43B | 7.51B | 7.57B | 7.67B |
| Cash & Short-term Investments | 849M | 438M | 445M | 588M | 729M | 660M |
| Cash Flow | ||||||
| Operating Cash Flow | 696M | 167M | 602M | 751M | 741M | 1.23B |
| Capital Expenditure | 208M | 271M | 262M | 319M | 212M | 189M |
| Free Cash Flow | 488M | -104M | 340M | 432M | 529M | 1.04B |
| Ratios | ||||||
| ROE | 6.7% | 6.5% | 4.3% | 4.2% | 4.0% | 9.8% |
| ROA | 4.0% | 3.7% | 2.5% | 2.5% | 2.4% | 6.1% |
| Net Profit Margin | 6.5% | 5.6% | 3.8% | 3.6% | 3.5% | 8.9% |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
Cenra Inc. dividends
- Dividend yield
- 3.08%
- Forward dividend
- 1.00 TWD
- Payout ratio
- 49.6%
- Ex-dividend date
- Jul 23, 2026
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | TWD 149M | 1.02 | 49.6% |
| 2024 | TWD 149M | 1.00 | 47.0% |
| 2023 | TWD 238M | 1.60 | 74.0% |
| 2022 | TWD 268M | 1.80 | 56.2% |
| 2021 | TWD 298M | 2.00 | 57.6% |
| 2008 | - | - | - |
| 2002 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Who owns Cenra Inc.
- Insiders 36.10%
- Institutions 4.31%
- Public & others 59.60%
- Shares outstanding 147M
- Free float 96.4M
Cenra Inc. company profile
- Company name
- Cenra Inc.
- Ticker
- 3716.TW
- Exchange
- Taiwan Stock Exchange
- Sector
- Healthcare
- Industry
- Medical Distribution
- Fiscal year end
- December
- Address
- No. 23, Xiangyang Road, Taipei, Taiwan, 10046
- Phone
- 886 2 2312 4200
- Website
- cenra.com
About Cenra Inc.
Cenra Inc. engages in the research and development, manufacture, and sale of generic pharmaceutical and healthcare products for humans and animals. It provides CDMO services for internal and external partners; oral solids, injectables, specialty formulations, and APIs, supported by process development, scale-up, and regulatory support; oral solids, injectables, specialty formulations, and high-purity active pharmaceutical ingredients (APIs), supported by process development, scale-up, and regulatory support; distribution, and marketing for prescription drugs, OTC products, health supplements, personal care products, and medical devices;home care, caregiver training, and consulting for elderly support; develops and manufactures veterinary pharmaceuticals, and animal health products for livestock and companion animals and offers CDMO services for animal health partners. Cenra Inc. was founded in 2024 and is headquartered in Taipei, Taiwan.
Cenra Inc. management
6- Mr. Hou-Kai WangGeneral Manager & Director
- Mr. Chih-Yung WuPresident
- Chao-Lang LinDirector of Finance Department
- Mr. Te-Feng ChaoDirector of Administrative Support Department
- Mr. Teng-Pao LinChief Auditor
- Mr. Yin-Nan SunVP, Deputy GM & President of Chunghwa Yuming Healthcare Co Ltd